The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
about
Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies.Correlation analysis of mesenchymal-epithelial transition factor protein and human epidermal growth receptor 2 protein expression in 1479 cases of lung adenocarcinoma in China.Synergistic antitumor activity of low-dose c-Met tyrosine kinase inhibitor and sorafenib on human non-small cell lung cancer cells.Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab.
P2860
The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
The HGF/c-MET Pathway Is a Dri ...... in Non-Small Cell Lung Cancer.
@en
The HGF/c-MET Pathway Is a Dri ...... in Non-Small Cell Lung Cancer.
@nl
type
label
The HGF/c-MET Pathway Is a Dri ...... in Non-Small Cell Lung Cancer.
@en
The HGF/c-MET Pathway Is a Dri ...... in Non-Small Cell Lung Cancer.
@nl
prefLabel
The HGF/c-MET Pathway Is a Dri ...... in Non-Small Cell Lung Cancer.
@en
The HGF/c-MET Pathway Is a Dri ...... in Non-Small Cell Lung Cancer.
@nl
P2093
P2860
P50
P1476
The HGF/c-MET Pathway Is a Dri ...... in Non-Small Cell Lung Cancer.
@en
P2093
Anderson J Ryan
Babita Saigal
Emer Hanrahan
Hai T Tran
Heather Y Lin
Humam Kadara
Jack J Lee
Ju-Seog Lee
Juliane M Jüergensmeier
P2860
P304
P356
10.1158/1078-0432.CCR-16-3216
P407
P577
2017-05-30T00:00:00Z